Meeting
2020 ASCO Virtual Scientific Program
Final results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma.
Authors
Dashan Ai
Fudan University Shanghai Cancer Center, Shanghai, China
Dashan Ai , Jinjun Ye , Yun Chen , Qi Liu , Xiangpeng Zheng , Yunhai Li , Shihong Wei , Jiancheng Li , Qin Lin , Hui Luo , Jianzhong Cao , Jialiang Zhou , Guang Huang , Min Fan , Kailiang Wu , Huanjun Yang , Zhengfei Zhu , Weixin Zhao , Ling Li , Kuaile Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02459457
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4564)
DOI
10.1200/JCO.2020.38.15_suppl.4564
Abstract #
4564
Poster Bd #
172
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).
First Author: Dashan Ai
Poster
2022 ASCO Annual Meeting
Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.
First Author: Ajaykumar Singh
Poster
2018 ASCO Annual Meeting
Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).
First Author: Yun Chen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).
First Author: Satoru Matsuda